Incyte Corp Form 4 Filings

INCYTE CORP (INCY) reported that officer Pablo J. Cagnoni, President, Global Head of R&D, sold 10,801 shares of common stock on 2026-08-19 in an open-market transaction at $125.56 per share, pursuant to a Rule 10b5-1 trading plan. Following this sale, he holds rights to 183,200 shares of common stock issuable from previously reported restricted stock units and earned performance stock units that have not yet vested.

Incyte Corp reported that President, Global Head of R&D Pablo J. Cagnoni sold 10,803 shares of common stock on 2026-08-12 at $120.04 per share in an open-market transaction under a Rule 10b5-1 trading plan. Following this sale, he reported 194,001 shares held directly, including 183,200 shares issuable from unvested restricted and performance stock units.

Pablo J. Cagnoni, President and Global Head of R&D at Incyte, reported selling 10,640 shares of common stock on August 5, 2026 at $122.69 per share in a code S open-market or private transaction executed under a Rule 10b5-1 trading plan. Following the sale, he reports ownership of 204,804 shares, including 183,200 shares issuable from previously reported, unvested restricted stock units and earned performance stock units.

INCYTE CORP EVP & Chief Scientific Officer Patrick A. Mayes exercised employee stock options covering 2,207 shares at $106.47 on August 5, 2026, then sold 2,207 common shares at $123.99 per share under a Rule 10b5-1 trading plan.

Footnotes state the option award was fully vested and exercisable as of that date and note 59,537 shares of common stock issuable from previously reported restricted stock units that have not vested.

Incyte Corp executive Pablo J. Cagnoni, President and Global Head of R&D, reported selling 15,888 shares of common stock on 2026-07-31 at $119.70 per share in an open market or private transaction. After the sale, he directly holds 215,444 shares, including 183,200 shares issuable from previously reported restricted stock units and earned performance stock units that have not vested. The transaction was made under a Rule 10b5-1 trading plan.

Patrick A. Mayes, EVP & Chief Scientific Officer of Incyte, exercised employee stock options covering 45,767 shares and acquired common stock, then reported sale transactions totaling 47,954 shares of common stock on July 31 and August 3, 2026, pursuant to a Rule 10b5-1 trading plan.

The exercised options included grants with exercise prices of $61.18, $72.27 and $105.43 per share. Footnotes state his reported holdings also include 59,537 additional shares underlying unvested restricted stock units.

Michael James Morrissey, EVP and Head of Technical Operations at Incyte, received two equity awards on July 23, 2026. He was granted 6,426 stock options with a $116.69 exercise price, vesting 25% after one year then monthly over three years, expiring July 22, 2036. He also received 8,999 performance shares, each representing the right to receive up to 200% of one common share based on relative three-year TSR versus a fixed peer group, with earned shares vesting on the third anniversary of the grant, subject to continued service.

Incyte Corp EVP and Head of Incyte International Heeson Lee received new equity awards on July 23, 2026: 15,423 employee stock options at a $116.69 exercise price, expiring in 2036, and 13,498 performance shares, all reported as directly owned.

The options vest 25% after one year, then monthly over three years. Each performance share represents up to 200% of one common share, earned on relative total shareholder return over a three-year period starting January 1, 2026, with earned shares vesting on the third grant anniversary.

Incyte Corp reported that Principal Accounting Officer Tray Thomas received equity awards on July 16, 2026. He was granted 2,834 restricted stock units (RSUs), vesting 25% annually over four years, and 4,079 employee stock options with a $116.65 exercise price, expiring July 15, 2036, vesting 25% after one year then monthly over three years. Following these grants he directly holds 21,699 common shares, including 13,070 shares issuable from previously reported unvested RSUs.

Steven H. Stein, Incyte's CMO and Head of Late-Stage Development, reported July 16, 2026 equity activity including grants of 9,798 restricted stock units, 24,496 performance shares, and 42,298 stock options with an exercise price of 116.6500 per share, plus a sale of 1,877 common shares at 114.7300 per share. These transactions were made under a Rule 10b5-1 trading plan. The RSUs vest 25% annually over four years, the options vest over four years in 37 installments, and performance shares may earn up to 200% of one share based on three-year relative TSR versus a peer group.

Mayes Patrick A reported acquisition or exercise transactions in this Form 4 filing.

Incyte Corp EVP & Chief Scientific Officer Patrick A. Mayes received equity awards on July 16, 2026, including 5,916 restricted stock units vesting 25% annually over four years, 25,538 stock options at $116.65 per share expiring July 15, 2036, and 14,790 performance shares tied to relative total shareholder return over a three-year period. Following the RSU award, he directly holds 63,628 shares of common stock.

INCYTE CORP’s President, Global Head of R&D Pablo J. Cagnoni received equity compensation awards on July 16, 2026, including 13,403 restricted stock units, 57,861 employee stock options at an exercise price of $116.65 per share, and 33,508 performance shares.

After these awards, he directly holds 231,332 common shares, including 183,200 shares issuable under unvested restricted stock units and earned performance stock units. The RSUs vest 25% annually over four years, options vest over four years, and performance shares may deliver up to 200% of a share based on three-year relative TSR.

INCYTE CORP executive Mohamed Khairie Issa, EVP and Head of U.S. Commercial, reported equity grants and a small stock sale. He received 7,857 restricted stock units vesting 25% annually over four years, for a total of 71,797 unvested RSU-based shares, plus 33,918 stock options at an exercise price of $116.65 and 19,643 performance shares linked to relative total shareholder return. On the same date, he sold 1,093 common shares at $115.01, leaving 63,940 shares held directly. The filing indicates these transactions were effected under a Rule 10b5-1 trading plan.

Incyte Corp EVP, Human Resources Ramitpal K. Basi received multiple equity awards. On July 16, 2026, he was granted 4,991 restricted stock units vesting 25% annually over four years, 21,548 employee stock options with a $116.65 exercise price vesting over four years, and 12,479 performance shares that may deliver up to 200% of one share each based on relative total shareholder return over a three-year period. In total, 11,497 shares of common stock are issuable upon vesting of his outstanding restricted stock units.

Gardner David H reported acquisition or exercise transactions in this Form 4 filing.

Incyte EVP and Chief Strategy Officer David H. Gardner received equity awards on July 16, 2026, including 7,395 restricted stock units, 31,923 employee stock options at $116.65 per share, and 18,487 performance shares tied to Incyte common stock.

The RSUs vest 25% annually over four years, the options become exercisable 25% after one year and then monthly over three years, and the performance shares can deliver up to 200% of a share each based on three-year TSR performance, with earned shares vesting on the third anniversary of the grant.

INCYTE CORP executive Richard A. Hoffman, EVP & General Counsel, received multiple equity awards on July 16, 2026. He was granted 7,395 restricted stock units vesting 25% annually over four years, bringing unvested RSU-linked common shares to 16,861. He also received options on 31,923 shares at an exercise price of $116.65 expiring July 15, 2036, vesting 25% after one year and then monthly over three years, plus 18,487 performance shares that can pay up to 200% of one common share each based on relative TSR over a three-year period starting January 1, 2026.

INCYTE CORP Chief Executive Officer William Meury received multiple equity awards on July 16, 2026. He was granted 26,807 restricted stock units that vest 25% annually over four years, 77,148 stock options with a $116.65 exercise price, and 80,421 performance shares that can deliver up to 200% of one share each based on relative total shareholder return over a three-year period.

Following these awards, his direct common stock exposure totals 183,129 shares, including 178,883 shares issuable from previously reported unvested restricted stock units and earned performance stock units.

INCYTE CORP executive Pablo J. Cagnoni, President and Global Head of R&D, reported two F-code tax-withholding dispositions of common stock tied to settlements of restricted stock units and earned performance shares, totaling 22,919 shares at prices of $114.88 and $115.09 per share. After these withholdings, he directly holds 217,929.0000 shares of common stock, and his reported holdings include 169,797 shares issuable from unvested restricted stock units and earned performance shares.

INCYTE CORP EVP & Chief Scientific Officer Patrick A Mayes reported automatic tax-withholding dispositions totaling 1,949 shares of common stock on July 14–15, 2026, to satisfy RSU-related tax obligations. Following these withholdings, he directly holds 57,712 shares, including 53,621 issuable from unvested restricted stock units.

INCYTE CORP Principal Accounting Officer Tray Thomas reported two tax-withholding dispositions of common stock related to restricted stock unit settlements, totaling 1,790 shares on July 14–15, 2026. After these withholdings, Thomas holds 18,865 shares directly, including 10,236 shares issuable from unvested restricted stock units.

INCYTE CORP executive Steven H. Stein, CMO & Head of Late-Stage Development, reported multiple common stock transactions. On July 15, 2026, he completed an open-market sale of 28,237 shares at $113.05 per share. On July 14 and 15, a total of 24,918 shares were disposed of through automatic tax withholding tied to the settlement of restricted stock units (RSUs) and earned performance shares, rather than discretionary market sales. Following the reported open-market sale, he reported holding 26,083 shares of common stock directly, and his beneficial ownership figure includes 19,540 shares issuable from unvested RSUs and earned performance-share awards.

Incyte Corp executive Mohamed Khairie, EVP and Head of U.S. Commercial, reported a tax-related share disposition. On 2026-07-15, 1,099 common shares were automatically withheld by the company at $115.09 per share to satisfy RSU tax withholding obligations. Following this withholding, Khairie holds 65,033 shares directly, including 63,940 shares issuable from unvested restricted stock units.

INCYTE CORP executive Patrick A. Mayes had 350 shares of common stock withheld by the company to cover tax obligations tied to restricted stock units. The withholding price was $116.86 per share. After this non-market tax-withholding event, he directly holds 59,661 shares of common stock.

A footnote also notes 58,730 additional shares are issuable from unvested restricted stock units, which are not yet settled into common stock.

INCYTE CORP Principal Accounting Officer Tray Thomas had 477 shares of common stock withheld on a recent restricted stock unit settlement. These shares were automatically retained by the company to cover tax withholding obligations, not sold on the open market. After this tax-withholding disposition, Thomas directly holds 20,655 shares, including 14,128 shares tied to unvested restricted stock units.

INCYTE CORP Chief Executive Officer and President William Meury reported a routine tax-related share disposition. On July 2, 2026, 4,779 shares of common stock were withheld at $116.86 per share to cover tax obligations tied to previously granted RSUs and earned performance shares.

After this automatic withholding, Meury directly owns 156,322 shares of common stock. Footnotes state this total includes 152,076 shares issuable from restricted stock units and earned performance shares that have not yet vested, highlighting that most of his reported position remains unvested equity awards rather than freely tradable shares.

INCYTE CORP chief medical officer Steven H. Stein reported an automatic share withholding to cover taxes tied to equity compensation. On this Form 4, 2,177 shares of common stock were withheld at an indicated value of $116.86 per share to satisfy tax withholding obligations when restricted stock units or earned performance shares settled.

After this tax-withholding disposition, Stein directly holds 76,150 shares of common stock. Footnote disclosure adds that his position also includes 73,591 shares of common stock underlying previously reported restricted stock units and earned performance shares that have not yet vested. This event reflects compensation-related tax treatment rather than an open-market sale.

BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.

INCYTE CORP reported that investment entities affiliated with Baker Bros. Advisors received a grant of 400 shares of Common Stock as director compensation in lieu of a $40,500 quarterly retainer. Following this award, Baker Bros.–related funds report indirect holdings of up to 28,205,760 Incyte shares, while Julian and Felix Baker also hold additional direct and partnership stakes.

Clancy Paul J reported acquisition or exercise transactions in this Form 4 filing.

INCYTE CORP director Paul J. Clancy received 252 shares of common stock as a grant under the company’s Amended and Restated 2010 Stock Incentive Plan. The award was issued in lieu of quarterly director retainer fees pursuant to an election intended to comply with Rule 10b5-1, and the restricted shares are fully vested.

Following this grant, Clancy directly holds 25,635 shares of common stock, which includes 1,642 shares underlying previously reported restricted stock units that have not yet vested. This filing reflects routine equity compensation rather than an open-market purchase or sale.

HARRIGAN EDMUND reported acquisition or exercise transactions in this Form 4 filing.

INCYTE CORP director Edmund Harrigan received 255 shares of common stock as a fully vested restricted stock grant. The shares were issued under Incyte’s Amended and Restated 2010 Stock Incentive Plan in lieu of his quarterly director retainer fees, pursuant to an election intended to comply with Rule 10b5-1. After this grant, he beneficially owns 23,019 shares of common stock, which includes 1,642 shares issuable from previously reported restricted stock units that have not yet vested.

BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.

INCYTE CORP director representative entities report equity awards tied to Julian C. Baker’s board service. On June 8, 2026, Baker-related fund entities were granted 1,642 restricted stock units and 6,111 non-qualified stock options linked to Incyte common stock as director compensation.

The stock options carry a $100.64 strike price and expire on June 7, 2036. Both the RSUs and options vest on the earlier of June 8, 2027, the next Incyte annual stockholder meeting, or a change in control, subject to Julian C. Baker’s continued board service. The filing states Baker Bros. Advisors LP has voting and dispositive power over these awards, while Julian C. Baker and Felix J. Baker are described as having only indirect pecuniary interests through their fund and general partner ownership.

INCYTE CORP director Edmund Harrigan received new equity awards as part of his compensation. He was granted 1,642 restricted stock units that settle one-for-one into common shares, bringing his direct common stock holdings to 22,764 shares after the award.

He also received a non-qualified stock option covering 6,111 shares of common stock at an exercise price of $100.64 per share. Both the RSUs and the option vest in full on the first anniversary of the grant date, or earlier upon the next regular annual stockholder meeting or a change of control, with the option expiring on June 7, 2036.

INCYTE CORP director Paul J. Clancy received new equity awards as part of his compensation. He was granted 1,642 shares of common stock in the form of restricted stock units, which vest in full on the first anniversary of the grant date, or earlier if the next regular annual stockholder meeting occurs or there is a change of control. He also received a non-qualified stock option for 6,111 shares of common stock at an exercise price of $100.64 per share, with the same vesting schedule. Following these awards, he holds 25,383 shares of common stock directly.

Incyte Corp director Jacqualyn A. Fouse received new equity awards consisting of restricted stock units and stock options. She was granted 1,642 RSUs that vest in full on the first anniversary of the grant date, or earlier if the next regular annual stockholder meeting occurs first, or upon a change of control as defined in the RSU plan. The RSUs settle into common stock on a one-for-one basis. She also received a non-qualified stock option for 6,111 shares of common stock at an exercise price of $100.64 per share, vesting on the same schedule and expiring in 2036. Following these awards, she directly holds 20,968 shares of common stock.

INCYTE CORP director Jean Jacques Bienaimé received new equity awards consisting of restricted stock units and stock options. He was granted 1,642 RSUs that may be settled one-for-one in common stock and 6,111 non-qualified stock options with an exercise price of $100.64 per share.

The RSUs and options each vest in full on the first anniversary of the grant date or, if earlier, on the date of the next regular annual meeting of stockholders or upon a change of control, as defined in the applicable plans. Following these RSU grants, his direct common stock holdings total 24,424 shares.

INCYTE CORP director Katherine A. High reported equity compensation awards rather than open-market trading. She received 1,642 restricted stock units that each convert into one share of common stock, and these RSUs vest in full on the first anniversary of the grant, or earlier if the next regular annual stockholders’ meeting or a change of control occurs.

She was also granted a non-qualified stock option covering 6,111 shares of common stock at an exercise price of $100.64 per share, vesting on the same schedule and expiring in 2036. Following these awards, she directly holds 14,983 shares of common stock, plus the new option grant.

INCYTE CORP director Otis W. Brawley received new equity awards as part of his compensation. He was granted 1,642 restricted stock units of common stock that vest in full on the first anniversary of the grant date, or earlier upon the next annual stockholder meeting or a change of control. He also received a non-qualified stock option for 6,111 shares of common stock at an exercise price of $100.64 per share, vesting on the same schedule and expiring on June 7, 2036. Following these awards, his direct common stock holdings total 12,894 shares.

INCYTE CORP Principal Accounting Officer Tray Thomas reported an exercise-and-sale transaction in company stock. On June 4, 2026, Thomas exercised a non-qualified stock option for 2,639 shares of common stock at an exercise price of $83.83 per share, then sold 2,639 shares in an open-market transaction at $100.00 per share.

After these transactions, Thomas directly holds 21,132 shares of common stock. This total includes 15,166 shares issuable from previously reported restricted stock units that have not yet vested, indicating that a large portion of the position remains tied to equity compensation awards.

INCYTE CORP executive Pablo J. Cagnoni reported a tax-related share disposition. On the settlement of previously granted restricted stock units, 25,469 shares of common stock were automatically withheld by the company to cover tax withholding obligations at a price of $95.59 per share. After this withholding, he directly holds 240,848 shares, and this figure includes 213,078 shares tied to unvested restricted stock units and earned performance shares.

INCYTE CORP Principal Accounting Officer Tray Thomas reported an open-market sale of 2,051 shares of common stock at $97.35 per share. After this transaction, Thomas directly holds 21,132 shares. A footnote states that these holdings include 15,166 shares issuable from previously reported, unvested restricted stock units.

INCYTE CORP director Jean-Jacques Bienaimé reported routine equity compensation activity. On May 26, 2026, he exercised 15,000 shares of non-qualified stock options at an exercise price of $84.53 per share, converting an option award into common stock.

On the same date, 13,059 shares of common stock were automatically withheld by the company at $97.10 per share to cover the cost of exercising the option and related tax obligations, rather than being sold in the open market. The filing also notes previously reported restricted stock units that have not yet vested.

INCYTE CORP director Paul J. Clancy completed an option exercise and share sale. On May 19, 2026, he exercised non-qualified stock options to acquire 15,000 shares of common stock at $84.53 per share and sold 15,000 shares at $94.93 per share in an open-market transaction.

After these transactions, he directly owned 23,741 shares of common stock. This figure includes 2,518 shares issuable from previously reported restricted stock units that have not yet vested.

Stein Steven H reported acquisition or exercise transactions in this Form 4 filing.

Incyte Corp chief medical officer Steven H. Stein reported an amended insider transaction showing he earned 44,124 shares of common stock tied to performance shares. The compensation committee determined on May 6, 2026 that specified development, revenue and market-based goals had been achieved.

The earned shares will vest on the third anniversary of the July 14, 2023 grant date, as long as he continues serving the company. Including this certification, Stein now has 78,327 shares of common stock issuable from previously reported restricted stock units and earned performance shares that have not yet vested.

INCYTE CORP reported that President and Global Head of R&D Pablo J. Cagnoni acquired 31,517 shares of common stock through a grant of earned performance shares on May 6, 2026. These shares relate to performance criteria determined to be satisfied on that date and carry no purchase price.

The earned shares will vest on the third anniversary of the original July 14, 2023 grant date, if he continues serving the company. Over the three-year performance period, the number of shares he may receive ranges from 0% to 150% of the performance shares awarded, based on development, revenue and market-based goals tied to relative total shareholder returns versus the Nasdaq Biotechnology Index.

After this certification, Cagnoni holds 266,317 shares directly, including 261,178 shares of common stock issuable from previously reported restricted stock units and earned but unvested performance shares. This Form 4/A amends an earlier filing to reflect the Compensation Committee’s updated performance determination on May 6, 2026.

INCYTE CORP insiders linked to Baker Bros. reported routine equity compensation activity. Entities associated with 667, L.P. and Baker Brothers Life Sciences LP exercised in total 30,000 non-qualified stock options at an exercise price of $84.53 per share, receiving the same number of Incyte common shares.

The options were originally granted to director Julian C. Baker for board service, but under advisory policies he has no direct pecuniary interest in these awards or the shares issued. The related funds and their affiliates instead hold indirect proportionate pecuniary interests, while Baker Bros. Advisors LP has voting and dispositive power over these securities.

After these exercises, the funds report indirect holdings of 28,203,718 and 2,833,039 Incyte shares, alongside direct holdings of 281,190 and 278,773 shares by Julian and Felix Baker and 33,410 shares held by FBB Associates. No open-market purchases or sales are disclosed in this filing.

INCYTE CORP executive vice president and chief financial officer Suketu Upadhyay received new equity awards as part of his compensation. He was granted 26,343 restricted stock units, vesting 25% annually over four years and settling one-for-one in common shares.

He also received 13,171 performance shares, which can deliver up to 200% of one common share each based on relative total shareholder return over a three-year period beginning January 1, 2026, with earned shares vesting on the third anniversary of the grant. In addition, he was granted 38,429 stock options with a $97.14 exercise price, vesting 25% after one year and the remainder in monthly installments over the next three years, and expiring on May 4, 2036.

INCYTE CORP’s President and Global Head of R&D, Pablo J. Cagnoni, reported an exercise-and-sell transaction in company stock. On April 17, 2026, he exercised employee stock options to acquire a total of 18,667 shares of common stock at strike prices of $71.93 and $64.25 per share, then completed an open-market sale of 18,667 shares at an average price of $96.50 per share.

Following these transactions, he directly held 262,692 shares of INCYTE common stock. A footnote states that this amount includes 257,553 shares of common stock issuable from previously reported restricted stock units and earned performance stock units that have not yet vested, highlighting a substantial remaining equity stake tied to future service and performance conditions.

Meury William reported acquisition or exercise transactions in this Form 4 filing.

INCYTE CORP Chief Executive Officer William Meury reported an equity award tied to performance shares. On April 15, 2026, 125,000 shares of common stock were earned based on performance criteria and are underlying performance shares. These earned shares are scheduled to vest on July 2, 2026, provided he continues serving the company.

The filing notes each performance share represents the right to receive up to 400% of one share of common stock, subject to pre-established performance and vesting conditions over a six-year performance period. After this award, 161,101 shares of common stock are shown as issuable under previously reported restricted stock units and earned performance shares that have not yet vested.

CAGNONI PABLO J reported acquisition or exercise transactions in this Form 4 filing.

INCYTE CORP President and Global Head of R&D Pablo J. Cagnoni reported an equity award of 27,892 shares of common stock. These shares were earned from performance share units after performance criteria were determined to be satisfied on April 15, 2026.

The earned shares are scheduled to vest on the third anniversary of the original July 14, 2023 grant date, subject to his continued service with the company. Following this award, he holds 262,692 shares of common stock, including 257,553 shares tied to previously reported unvested restricted stock units and earned performance stock units.

INCYTE CORP reported that CMO & Head of Late-Stage Development Steven H. Stein acquired 39,049 shares of common stock at no cost through earned performance shares. These shares relate to performance criteria determined to be satisfied on April 15, 2026 and will vest on the third anniversary of the July 14, 2023 grant date, subject to his continued service. After this award, he holds rights to 73,252 shares of common stock issuable under previously reported restricted stock units and earned performance shares that have not yet vested.